1. Procop GW, Church DL, Hall GS, et al. Koneman’s color atlas and textbook of diagnostic microbiology. 7th edition. Philadelphia: Wolters Kluwer; 2017.
2. Que Y-A, P M. Staphylococcus aureus (including staphylococcal toxic shock syndrome). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, douglas, and bennett’s prin-
ciples and practice of infectious diseases. 9th edition ed. Philadelphia: Elsevier; 2020.
3. Rupp ME, D. FP. Staphylococcus epidermidis and other coagulase-negative staphylococci. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, douglas, and bennett’s
principles and practice of infectious diseases. 9th edition ed. Philadelphia: Elsevier; 2020.
4. Becker K, Skov RL, Von Eiff C. Staphylococcus, micrococcus, and other catalase-positive cocci. In: Jorgensen JH, Pfaller MA, eds. Manual of clinical microbiology. 11th edition
ed. Washington, D.C.: ASM Press; 2015.
5. Ross AA, Rodrigues Hoffmann A, Neufeld JD. The skin microbiome of vertebrates. Microbiome. 2019; 7(1): 79.
6. Chong CE, Bengtsson RJ, Horsburgh MJ. Comparative genomics of staphylococcus capitis reveals species determinants. Front Microbiol. 2022; 13: 1005949.
7. Kloos WE, Bannerman TL. Update on clinical significance of coagulase-negative staphylococci. Clin Microbiol Rev. 1994; 7(1): 117-140.
8. Kozajda A, Jezak K, Kapsa A. Airborne staphylococcus aureus in different environments-a review. Environmental Science & Pollution Research International. 2019;
26(34): 34741-34753.
9. Heilmann C, Ziebuhr W, Becker K. Are coagulase-negative staphylococci virulent? Clinical Microbiology & Infection. 2019; 25(9): 1071-1080.
10. Franca A, Gaio V, Lopes N, Melo LDR. Virulence factors in coagulase-negative staphylococci. Pathogens. 2021; 10(2).
11. Bastos MD, Coutinho BG, Coelho ML. Lysostaphin: A staphylococcal bacteriolysin with potential clinical applications. Pharmaceuticals (Basel). 2010; 3(4): 1139-1161.
12. Gonzalez-Martin M, Corbera JA, Suarez-Bonnet A, Tejedor-Junco MT. Virulence factors in coagulase-positive staphylococci of veterinary interest other than staphylococ-
cus aureus. Vet Q. 2020; 40(1): 118-131.
13. Chu DM, Ma J, Prince AL, et al. Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery.
Nat Med. 2017; 23(3): 314-326.
14. Schoch JJ, Monir RL, Satcher KG, et al. The infantile cutaneous microbiome: A review. Pediatr Dermatol. 2019; 36(5): 574-580.
15. Raineri EJM, Altulea D, van Dijl JM. Staphylococcal trafficking and infection-from ‘nose to gut’ and back. FEMS Microbiol Rev. 2022; 46(1).
16. Maltezou HC, Giamarellou H. Community-acquired methicillin-resistant staphylococcus aureus infections. Int J Antimicrob Agents. 2006; 27(2): 87-96.
17. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al. Methicillin-resistant staphylococcus aureus: An overview of basic and clinical research. Nat Rev Microbiol.
2019; 17(4): 203-218.
18. Dundar D, Willke A, Sayan M, et al. Epidemiological and molecular characteristics of meticillin-resistant staphylococcus aureus in turkey: A multicentre study. J Glob
Antimicrob Resist. 2016; 6: 44-49.
19. Tan L, Li SR, Jiang B, Hu XM, Li S. Therapeutic targeting of the staphylococcus aureus accessory gene regulator (agr) system. Front Microbiol. 2018; 9: 55.
20. Dayan N. Skin microbiome handbook: From basic research to product development. 1st edition. Beverly: Scrivener Publishing LLC; 2020.
21. Moormeier DE, Bayles KW. Staphylococcus aureus biofilm: A complex developmental organism. Mol Microbiol. 2017; 104(3): 365-376.
22. Cheung GYC, Bae JS, Otto M. Pathogenicity and virulence of staphylococcus aureus. Virulence. 2021; 12(1): 547-569.
23. Bukowski M, Wladyka B, Dubin G. Exfoliative toxins of staphylococcus aureus. Toxins (Basel). 2010; 2(5): 1148-1165.
24. Argemi X, Hansmann Y, Riegel P, Prevost G. Is staphylococcus lugdunensis significant in clinical samples? J Clin Microbiol. 2017; 55(11): 3167-3174.
25. Otto M. Staphylococcus epidermidis–the ‘accidental’ pathogen. Nat Rev Microbiol. 2009; 7(8): 555-567.
26. Kocianova S, Vuong C, Yao Y, et al. Key role of poly-gamma-dl-glutamic acid in immune evasion and virulence of staphylococcus epidermidis. J Clin Invest. 2005;
115(3): 688-694.
27. de Paiva-Santos W, de Sousa VS, Giambiagi-deMarval M. Occurrence of virulence-associated genes among staphylococcus saprophyticus isolated from different sour-
ces. Microb Pathog. 2018; 119: 9-11.
28. Kahl BC, Becker K, Loffler B. Clinical significance and pathogenesis of staphylococcal small colony variants in persistent infections. Clin Microbiol Rev. 2016; 29(2):
401-427.
29. Schlievert PM, Blomster DA. Production of staphylococcal pyrogenic exotoxin type c: Influence of physical and chemical factors. J Infect Dis. 1983; 147(2): 236-242.
30. Spaulding AR, Salgado-Pabon W, Kohler PL, et al. Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev. 2013; 26(3): 422-447.
31. Centers for disease control and prevention. Toxic shock syndrome (other than streptococcal) (tss). 2011 [cited 15.12.2023]; Available from: https://ndc.services.cdc.gov/case-de-
finitions/toxic-shock-syndrome-2011/
32. Becker K, Both A, Weisselberg S, Heilmann C, Rohde H. Emergence of coagulase-negative staphylococci. Expert Rev Anti Infect Ther. 2020; 18(4): 349-366.
33. Michels R, Last K, Becker SL, Papan C. Update on coagulase-negative staphylococci-what the clinician should know. Microorganisms. 2021; 9(4).
34. Osaki S, Kikuchi K, Moritoki Y, et al. Distinguishing coagulase-negative staphylococcus bacteremia from contamination using blood-culture positive bottle detection
pattern and time to positivity. J Infect Chemother. 2020; 26(7): 672-675.
35. Ishiekwene C, Ghitan M, Kuhn-Basti M, Chapnick E, Lin YS. Staphylococcus lugdunensis endocarditis with destruction of the ventricular septum and multiple native
valves. IDCases. 2017; 7: 14-15.
36. Petti CA, Simmon KE, Miro JM, et al. Genotypic diversity of coagulase-negative staphylococci causing endocarditis: A global perspective. J Clin Microbiol. 2008; 46(5):
1780-1784.
37. Popa-Fotea NM, Scafa-Udriste A, Iulia G, et al. Increasing clinical impact and microbiological difficulties in diagnosing coagulase-negative staphylococci in infective endocar-
ditis – a review starting from a series of cases. Current Medical Research & Opinion. 2022; 38(12): 2077-2083.
38. Yu J, Tien N, Liu YC, et al. Rapid identification of methicillin-resistant staphylococcus aureus using maldi-tof ms and machine learning from over 20,000 clinical
isolates. Microbiol Spectr. 2022; 10(2): e0048322.
39. Gajdacs M. The continuing threat of methicillin-resistant staphylococcus aureus. Antibiotics (Basel). 2019; 8(2).
40. Lyon BR, Skurray R. Antimicrobial resistance of staphylococcus aureus: Genetic basis. Microbiol Rev. 1987; 51(1): 88-134.
41. Lowy FD. Antimicrobial resistance: The example of staphylococcus aureus. J Clin Invest. 2003; 111(9): 1265-1273.
42. Çetin ET, Anğ Ö. Staphylococci resistant to methicillin. Br Med J. 1962; (2): 51.
43. Chambers HF. Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications. Clin Microbiol Rev. 1997; 10(4): 781-791.
44. The european committee on antimicrobial susceptibility testing. Breakpoint tables for interpretation of mics and zone diameters. Version 13.1. 2023 29.06.2023 [cited
15.12.2023]; Available from: http://www.eucast.org
45. Dorr T. Understanding tolerance to cell wall-active antibiotics. Ann N Y Acad Sci. 2021; 1496(1): 35-58.
46. Miklasinska-Majdanik M. Mechanisms of resistance to macrolide antibiotics among staphylococcus aureus. Antibiotics (Basel). 2021; 10(11).
47. Gould IM, David MZ, Esposito S, et al. New insights into meticillin-resistant staphylococcus aureus (mrsa) pathogenesis, treatment and resistance. Int J Antimicrob
Agents. 2012; 39(2): 96-104.
48. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant staphylococcus
aureus infections in adults and children: Executive summary. Clin Infect Dis. 2011; 52(3): 285-292.
49. Clegg J, Soldaini E, McLoughlin RM, et al. Staphylococcus aureus vaccine research and development: The past, present and future, including novel therapeutic strate-
gies. Front Immunol. 2021; 12: 705360.
50. Ansari S, Jha RK, Mishra SK, Tiwari BR, Asaad AM. Recent advances in staphylococcus aureus infection: Focus on vaccine development. Infect Drug Resist. 2019; 12:
1243-1255.